89 related articles for article (PubMed ID: 32132383)
1. Digoxin lowers the incidence of prostate cancer: A nationwide population-based study.
Lin TP; Fan YH; Chen YC; Huang WJS
J Chin Med Assoc; 2020 Apr; 83(4):377-381. PubMed ID: 32132383
[TBL] [Abstract][Full Text] [Related]
2. A population-based study of the influence of socioeconomic status on prostate cancer diagnosis in Taiwan.
Wu CC; Lin CH; Chiang HS; Tang MJ
Int J Equity Health; 2018 Jun; 17(1):79. PubMed ID: 29903010
[TBL] [Abstract][Full Text] [Related]
3. Antiarrhythmic drug usage and prostate cancer: a population-based cohort study.
Kao LT; Huang CC; Lin HC; Huang CY
Asian J Androl; 2018; 20(1):37-42. PubMed ID: 28857052
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer risk among users of digoxin and other antiarrhythmic drugs in the Finnish Prostate Cancer Screening Trial.
Kaapu KJ; Murtola TJ; Määttänen L; Talala K; Taari K; Tammela TL; Auvinen A
Cancer Causes Control; 2016 Feb; 27(2):157-64. PubMed ID: 26573846
[TBL] [Abstract][Full Text] [Related]
5. Digoxin reduces the incidence of prostate cancer but increases the cancer-specific mortality: A systematic review and pooled analysis.
Zhao S; Li X; Wu W; Liu S; Shen M; Zhang Z; He J
Andrologia; 2021 Dec; 53(11):e14217. PubMed ID: 34414594
[TBL] [Abstract][Full Text] [Related]
6. Is digoxin use for cardiovascular disease associated with risk of prostate cancer?
Wright JL; Hansten PD; Stanford JL
Prostate; 2014 Jan; 74(1):97-102. PubMed ID: 24318956
[TBL] [Abstract][Full Text] [Related]
7. Sotalol, but not digoxin is associated with decreased prostate cancer risk: A population-based case-control study.
Kaapu KJ; Ahti J; Tammela TL; Auvinen A; Murtola TJ
Int J Cancer; 2015 Sep; 137(5):1187-95. PubMed ID: 25656312
[TBL] [Abstract][Full Text] [Related]
8. Impact of 5α-reductase inhibitor and α-blocker therapy for benign prostatic hyperplasia on prostate cancer incidence and mortality.
Van Rompay MI; Curtis Nickel J; Ranganathan G; Kantoff PW; Solomon KR; Lund JL; McKinlay JB
BJU Int; 2019 Mar; 123(3):511-518. PubMed ID: 30216624
[TBL] [Abstract][Full Text] [Related]
9. Does chronic obstructive pulmonary disease increase the risk of prostate cancer? A nationwide population-based study.
Hsu WL; Chen HY; Chang FW; Hsu RJ
Int J Chron Obstruct Pulmon Dis; 2019; 14():1913-1921. PubMed ID: 31686802
[TBL] [Abstract][Full Text] [Related]
10. The association between epididymo-orchitis and prostate cancer: A nationwide population-based cohort study.
Liu JM; Yi CC; Lin CY; Chang H; Hsu RJ; Chuang HC; Hsu WL
Medicine (Baltimore); 2019 May; 98(21):e15363. PubMed ID: 31124926
[TBL] [Abstract][Full Text] [Related]
11. Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
Haring A; Murtola TJ; Talala K; Taari K; Tammela TL; Auvinen A
Scand J Urol; 2017 Feb; 51(1):5-12. PubMed ID: 28084175
[TBL] [Abstract][Full Text] [Related]
12. Lower Urinary Tract Infection and Subsequent Risk of Prostate Cancer: A Nationwide Population-Based Cohort Study.
Fan CY; Huang WY; Lin KT; Lin CS; Chao HL; Yang JF; Lin CL; Kao CH
PLoS One; 2017; 12(1):e0168254. PubMed ID: 28046120
[TBL] [Abstract][Full Text] [Related]
13. Statin reduces the risk of dementia in diabetic patients receiving androgen deprivation therapy for prostate cancer.
Liu JM; Chen TH; Chuang HC; Wu CT; Hsu RJ
Prostate Cancer Prostatic Dis; 2019 May; 22(2):276-283. PubMed ID: 30337635
[TBL] [Abstract][Full Text] [Related]
14. Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: a nationwide cohort study of 3,009,258 men.
Ørsted DD; Bojesen SE; Nielsen SF; Nordestgaard BG
Eur Urol; 2011 Oct; 60(4):691-8. PubMed ID: 21705134
[TBL] [Abstract][Full Text] [Related]
15. Effect of alpha1-adrenoceptor antagonist exposure on prostate cancer incidence: an observational cohort study.
Harris AM; Warner BW; Wilson JM; Becker A; Rowland RG; Conner W; Lane M; Kimbler K; Durbin EB; Baron AT; Kyprianou N
J Urol; 2007 Nov; 178(5):2176-80. PubMed ID: 17870114
[TBL] [Abstract][Full Text] [Related]
16. Brachytherapy Boost Utilization and Survival in Unfavorable-risk Prostate Cancer.
Johnson SB; Lester-Coll NH; Kelly JR; Kann BH; Yu JB; Nath SK
Eur Urol; 2017 Nov; 72(5):738-744. PubMed ID: 28688613
[TBL] [Abstract][Full Text] [Related]
17. A cohort study of digoxin exposure and mortality in men with prostate cancer.
Flahavan EM; Sharp L; Bennett K; Barron TI
BJU Int; 2014 Feb; 113(2):236-45. PubMed ID: 23937513
[TBL] [Abstract][Full Text] [Related]
18. Digoxin use and following risk of psoriasis: A population-based cohort study in Taiwan.
Li IH; Pan KT; Wang WM; Chien WC; Shih JH; Kao LT
J Dermatol; 2020 May; 47(5):458-463. PubMed ID: 32141100
[TBL] [Abstract][Full Text] [Related]
19. Metformin significantly reduces incident prostate cancer risk in Taiwanese men with type 2 diabetes mellitus.
Tseng CH
Eur J Cancer; 2014 Nov; 50(16):2831-7. PubMed ID: 25201464
[TBL] [Abstract][Full Text] [Related]
20. Risk of Cardiovascular Ischemic Events After Surgical Castration and Gonadotropin-Releasing Hormone Agonist Therapy for Prostate Cancer: A Nationwide Cohort Study.
Chen DY; See LC; Liu JR; Chuang CK; Pang ST; Hsieh IC; Wen MS; Chen TH; Lin YC; Liaw CC; Hsu CL; Chang JW; Kuo CF; Huang WK
J Clin Oncol; 2017 Nov; 35(32):3697-3705. PubMed ID: 28968166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
